SCHEMBL3395796

SCHEMBL3395796

CC(=O)Nc1ccc(-c2cc(C(N)=O)c3[nH]nc(C4CCNCC4)c3c2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IKBKB O14920 4/20 0.47
CHUK O15111 2/20 0.47
USP30 Q70CQ3 1/20 0.39
DYRK1B Q9Y463 3/20 0.39
DYRK1A Q13627 2/20 0.39
PARP1 P09874 1/20 0.39
DHODH Q02127 1/20 0.39
CLK1 P49759 1/20 0.39
DYRK2 Q92630 1/20 0.39
FYN P06241 1/20 0.38
PRKCZ Q05513 1/20 0.38
PRKD2 Q9BZL6 1/20 0.38
CSF1R P07333 2/20 0.38
BTK Q06187 2/20 0.38
SIRT2 Q8IXJ6 1/20 0.38
HTT P42858 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
NISCH Q9Y2I1 1/20 0.37
CDC7 O00311 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3393280 0.90 IKBKB (0.47) IKBKBCHUKUSP30DYRK1BDYRK1A
SCHEMBL3391461 0.84 IKBKB (0.64) IKBKBCHUKCSF1RBTK
Hydrochloric Acid SCHEMBL3395054 0.83 IKBKB (0.63) IKBKBCHUKCSF1RBTK
SCHEMBL14365477 0.83 USP30 (0.40) IKBKBCHUKUSP30DYRK1BDYRK1A
SCHEMBL3396344 0.83 IKBKB (0.49) IKBKBCHUKPARP1CSF1RBTK
SCHEMBL3395713 0.82 PTPN2 (0.48) USP30HTTJAK2
SCHEMBL3396389 0.80 IKBKB (0.55) IKBKBCHUKBTKL3MBTL1
SCHEMBL3393077 0.79 IKBKB (0.47) IKBKBCHUKPARP1CSF1RBTK
SCHEMBL3391160 0.79 CHUK (0.48) IKBKBCHUKBTK
SCHEMBL3392371 0.78 MAPT (0.39) IKBKBCHUKUSP30BTK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501780-B2 Indazole carboxamides and their use GLAXOSMITHKLINE LLC (US) 2013-08-06 US disclosed
US-8501780-B2 Indazole carboxamides and their use GLAXOSMITHKLINE LLC (US) 2013-08-06 US disclosed
US-8501780-B2 Indazole carboxamides and their use GLAXOSMITHKLINE LLC (US) 2013-08-06 US disclosed
EP-1758578-B1 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE GLAXOSMITHKLINE LLC (US) 2010-12-29 EP disclosed
EP-1758578-B1 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE GLAXOSMITHKLINE LLC (US) 2010-12-29 EP disclosed
EP-1758578-A4 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE SMITHKLINE BEECHAM CORP (US) 2009-05-27 EP disclosed
US-20070281933-A1 Novel Indazole Carboxamides And Their Use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-06 US disclosed
US-20070281933-A1 Novel Indazole Carboxamides And Their Use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-06 US disclosed
US-20070281933-A1 Novel Indazole Carboxamides And Their Use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-06 US disclosed
CN-101005836-A Novel indazole carboxamides and their use SMITHKLINE BEECHAM CORP (US) 2007-07-25 CN disclosed
EP-1758578-A2 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE Smithkline Beecham Corporation (US) 2007-03-07 EP disclosed
WO-2006002434-A2 NOVEL INDAZOLE CARBOXAMIDES AND THEIR USE SMITHKLINE BEECHAM CORPORATION (US) 2006-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070281933-A1 Novel Indazole Carboxamides And Their Use IKBKG, IRAK2, NFKBIA IKBKB 8/4885CHUK 9/4885USP30 1055/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.